To the EditorWe have several comments about the recent study1 investigating the effect of
anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding in patients …

A critical aspect of clinical care is determining when to start and when to stop a treatment.
Clinicians and researchers have given more attention to the first decision because starting …

To the Editor: We believe that the study by Dr Ost and colleagues1 of duration of
anticoagulation following venous thromboembolism is missing important data on bleeding …

To the EditorThe review by Dr Wells and colleagues1 on the treatment of venous
thromboembolism requires some clarifications. Table 1 in the article summarized new oral …

To the Editor: Dr Kearon and colleagues1 compared the use of fixed-dose, weight-adjusted
unfractionated heparin and low-molecular-weight heparin for acute venous …

To the Editor: Dr Kearon and colleagues1 compared the use of fixed-dose, weight-adjusted
unfractionated heparin and low-molecular-weight heparin for acute venous …

Via this screening, only 43 of 187 patients (24.7%) in the placebo group were identified to
have thrombophilia compared with 597 of 1907 patients (31%) with a first episode of …

To the Editor: Dr Eichinger and colleagues1 found that D-dimer levels measured after a
single occurrence of idiopathic venous thromboembolism (VTE) were related to future risk of …

Patients receiving anticoagulation for venous thromboembolism (VTE) have varying risks of
recurrence on cessation of the therapy. Time from the most recent thrombotic event is …

Story From the Front Lines A 52-year-old woman with hypertension and type 2 diabetes
presented with right-sided groin pain after a fall. Her medications included lisinopril …